Intech Investment Management LLC Boosts Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Intech Investment Management LLC raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,279 shares of the medical equipment provider’s stock after purchasing an additional 1,244 shares during the quarter. Intech Investment Management LLC’s holdings in Intuitive Surgical were worth $9,466,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Mark Sheptoff Financial Planning LLC purchased a new position in Intuitive Surgical during the second quarter valued at approximately $37,000. Sienna Gestion increased its holdings in shares of Intuitive Surgical by 5.3% during the 2nd quarter. Sienna Gestion now owns 17,036 shares of the medical equipment provider’s stock valued at $7,575,000 after purchasing an additional 853 shares in the last quarter. Waterloo Capital L.P. increased its holdings in shares of Intuitive Surgical by 116.2% during the 2nd quarter. Waterloo Capital L.P. now owns 3,838 shares of the medical equipment provider’s stock valued at $1,707,000 after purchasing an additional 2,063 shares in the last quarter. Blair William & Co. IL lifted its stake in shares of Intuitive Surgical by 5.3% in the 2nd quarter. Blair William & Co. IL now owns 472,242 shares of the medical equipment provider’s stock valued at $210,077,000 after purchasing an additional 23,667 shares during the period. Finally, Zega Financial LLC grew its position in Intuitive Surgical by 18.9% during the second quarter. Zega Financial LLC now owns 2,184 shares of the medical equipment provider’s stock valued at $972,000 after buying an additional 347 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In related news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now directly owns 295 shares of the company’s stock, valued at approximately $145,113.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Amy L. Ladd sold 450 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now owns 821 shares of the company’s stock, valued at approximately $402,519.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock worth $25,528,753 over the last quarter. 0.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ISRG has been the topic of several recent analyst reports. Barclays increased their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. Morgan Stanley raised their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Truist Financial upped their target price on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Robert W. Baird lifted their price target on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Finally, The Goldman Sachs Group assumed coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 price objective for the company. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Trading Down 0.8 %

Intuitive Surgical stock opened at $486.20 on Friday. The company has a 50-day moving average price of $468.01 and a 200 day moving average price of $424.86. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.18. The stock has a market cap of $172.46 billion, a P/E ratio of 87.76, a PEG ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the firm earned $1.18 EPS. The business’s revenue was up 14.5% compared to the same quarter last year. As a group, analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.